Breaking News Instant updates and real-time market news.

CHKP

Check Point

$120.01

-9.56 (-7.38%)

18:26
04/18/19
04/18
18:26
04/18/19
18:26

Check Point billings, news business metrics moderated in Q1, says Jefferies

Jefferies analyst John DiFucci kept his Buy rating and $140 price target on Check Point after its Q1 results, saying that while its revenue growth was better than in the 5 prior quarters, "billings and new business metrics moderated from the last 2" quarters. The analyst believes that the shift to a "ratable revenue" likely pressured metrics and expects the top line growth to improve, also maintaining his view of the stock as a "top mid cap pick" in the space.

  • 18

    Apr

CHKP Check Point
$120.01

-9.56 (-7.38%)

03/26/19
MZHO
03/26/19
INITIATION
MZHO
Mizuho initiates security software with top picks Palo Alto, CyberArk, Rapid7
Mizuho analyst Gregg Moskowitz initiated coverage of nine Security Software companies. In his industry update note, titled "Welcome to the New Age of Software - Part II," he noted that "macro concerns remain very prevalent and 4Q tech fundamentals were uneven," but added that he expects "security companies will navigate these issues well, due in part to the fact that cybersecurity consistently ranks at or near the top of IT spending priorities by CIOs." The analyst concluded that "while hardly immune, we would expect security spend to be relatively resilient." Moskowitz noted that global security revenue is currently well in excess of $40B, and growing at a roughly high-single digit CAGR. However, Moskowitz also noted that the security market is very fragmented and contains many sub-segments. He sees four security themes that he believes will become increasingly important, and should help to underpin healthy growth in the sector in the coming years -- Zero Trust, Identity Management, Next-gen Endpoint, and Machine Learning/Automation. The analyst expects to see "generally similar levels of security M&A activity in 2019," although he noted that one variable that could cause this to skew higher would be a large security vendor takeout, which is a historical rarity. Moskowitz initiated three stocks with Buy ratings -- Palo Alto Networks (PANW), CyberArk Software (CYBR), and Rapid7 (RPD) -- and six stocks with Neutral ratings -- Check Point Software (CHKP), FireEye (FEYE), Fortinet (FTNT), Okta (OKTA), Proofpoint (PFPT), and Symantec (SYMC).
04/12/19
OTRG
04/12/19
UPGRADE
OTRG
Positive
Check Point upgraded to Positive from Mixed at OTR Global
OTR Global upgraded Check Point to Positive from Mixed following checks that indicate Q1 exceeded plan in North American due to existing customer expansions, brand strength, and new customer acquisitions.
04/15/19
DBAB
04/15/19
NO CHANGE
Target $125
DBAB
Hold
Check Point price target raised to $125 from $110 at Deutsche Bank
Deutsche Bank analyst Karl Keirstead raised his price target for Check Point Software to $125 from $110 following recent channel checks and keeps a Hold rating on the shares. The analyst summarizes Check Point's fundamental outlook as "status quo," and says investor sentiment has improved due to easier year-over-year compares and the year-to-date rally across the Software space.
04/15/19
OPCO
04/15/19
NO CHANGE
Target $145
OPCO
Outperform
Check Point price target raised to $145 from $130 at Oppenheimer
Oppenheimer analyst Shaul Eyal raised his price target for Check Point to $145 from $130 ahead of Q1 results. The analyst says his checks with 21 VARs across the U.S. and Europe indicate consistent execution and stabilizing trends should enable the company to meet or slightly exceed consensus revenue estimate, steady regional performance driven by ongoing traction of its mid/high-end appliances provides further support, and infinity continuing to be the focal product aimed at helping customers to do more with fewer resources. Further, Eyal points out that cloud continues to garner greater mindshare via CloudGuard/Dome9, easier year over year comps still provide a decent set-up, and Check Point's momentum seems supported by a still healthy IT spending environment. He reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

SNAP

Snap

$14.33

-0.415 (-2.82%)

15:42
12/09/19
12/09
15:42
12/09/19
15:42
Periodicals
Snapchat feature to allow users to 'deepfake you into GIFs,' Tech Crunch says »

Tech Crunch's Josh…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$342.06

6.21 (1.85%)

15:35
12/09/19
12/09
15:35
12/09/19
15:35
Hot Stocks
Senator Markey says Tesla Autopilot 'can't be allowed' to replace drivers »

U.S. Senator Ed Markey, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 07

    Jan

CASY

Casey's General Stores

$175.80

(0.00%)

15:34
12/09/19
12/09
15:34
12/09/19
15:34
Options
Caseys General Stores options imply 8.0% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

MSFT

Microsoft

$151.60

-0.17 (-0.11%)

15:33
12/09/19
12/09
15:33
12/09/19
15:33
Hot Stocks
Microsoft to shut down Wunderlist on May 6, 2020 »

Microsoft said in a blog…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

AQST

Aquestive Therapeutics

$7.89

-0.13 (-1.62%)

15:25
12/09/19
12/09
15:25
12/09/19
15:25
Conference/Events
Aquestive Therapeutics holds analyst & investor event w/conference call hookup »

Management and Key…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

PTLA

Portola Pharmaceuticals

$28.48

-0.74 (-2.53%)

15:24
12/09/19
12/09
15:24
12/09/19
15:24
Hot Stocks
Portola presents new interim Phase 2a data from study of cerdulatinib »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARQL

ArQule

$19.72

10.045 (103.88%)

15:21
12/09/19
12/09
15:21
12/09/19
15:21
Downgrade
ArQule rating change  »

ArQule downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

TOL

Toll Brothers

$41.50

0.62 (1.52%)

15:19
12/09/19
12/09
15:19
12/09/19
15:19
Options
Toll Brothers options imply 8.6% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
12/09/19
12/09
15:17
12/09/19
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
12/09/19
12/09
15:16
12/09/19
15:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DISH

Dish

$33.53

-0.06 (-0.18%)

15:15
12/09/19
12/09
15:15
12/09/19
15:15
Options
Dish put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGNX

MacroGenics

$9.87

0.19 (1.96%)

15:09
12/09/19
12/09
15:09
12/09/19
15:09
Hot Stocks
MacroGenics announces updated results from Phase 1/2 study of flotetuzumab »

MacroGenics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

MDB

MongoDB

$131.13

-0.09 (-0.07%)

15:04
12/09/19
12/09
15:04
12/09/19
15:04
Options
MongoDB options imply 14.8% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 18

    Dec

IMGN

ImmunoGen

$4.06

0.195 (5.05%)

15:03
12/09/19
12/09
15:03
12/09/19
15:03
Hot Stocks
ImmunoGen presents updated findings from Phase 1 study of IMGN632 at ASH meeting »

ImmunoGen announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:00
12/09/19
12/09
15:00
12/09/19
15:00
General news
U.S.-China trade/tariff uncertainty is still present »

U.S.-China trade/tariff…

NVS

Novartis

$92.68

0.6 (0.65%)

14:53
12/09/19
12/09
14:53
12/09/19
14:53
Hot Stocks
Novartis says Kymriah demonstrates consistent efficacy, safety outcomes »

Novartis announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

GILD

Gilead

$67.11

0.02 (0.03%)

14:51
12/09/19
12/09
14:51
12/09/19
14:51
Hot Stocks
Gilead's Kite says results ZUMA-2 trial support regulatory filings »

Kite, a Gilead company,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMDA

Gamida Cell

$5.10

0.01 (0.20%)

14:49
12/09/19
12/09
14:49
12/09/19
14:49
Hot Stocks
Gamida Cell announces results from Phase 1 clinical study of GDA-201 »

Gamida Cell announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFIX

Stitch Fix

$25.05

0.92 (3.81%)

14:49
12/09/19
12/09
14:49
12/09/19
14:49
Options
Stitch Fix options imply 24.0% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 11

    Dec

  • 12

    Dec

  • 19

    Dec

GILD

Gilead

$67.08

-0.01 (-0.01%)

14:47
12/09/19
12/09
14:47
12/09/19
14:47
Hot Stocks
Gilead's Kite announces findings from ongoing post-marketing study of Yescarta »

Kite, a Gilead company,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUAN

Nuance

$17.55

-0.34 (-1.90%)

14:45
12/09/19
12/09
14:45
12/09/19
14:45
Options
Nuance call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

GS

Goldman Sachs

$222.17

-2.4 (-1.07%)

, SFTBF

SoftBank

$0.00

(0.00%)

14:41
12/09/19
12/09
14:41
12/09/19
14:41
Periodicals
SoftBank taps Goldman for $1.75B financing to help revive WeWork, Bloomberg says »

SoftBank (SFTBF) has…

GS

Goldman Sachs

$222.17

-2.4 (-1.07%)

SFTBF

SoftBank

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jan

  • 26

    Feb

CBL

CBL & Associates

$1.12

-0.025 (-2.18%)

14:36
12/09/19
12/09
14:36
12/09/19
14:36
Hot Stocks
CBL & Associates closes sale of interest in the Outlet Shoppes at Atlanta »

CBL Properties announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

14:25
12/09/19
12/09
14:25
12/09/19
14:25
Options
Berkshire Hathaway call volume above normal and directionally bullish »

Bullish option flow…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
12/09/19
12/09
14:17
12/09/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.